KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2025)

Vertex Pharmaceuticals (VRTX) has 8 years of Long-Term Deferred Tax data on record, last reported at $2.9 billion in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 27.21% year-over-year to $2.9 billion; the TTM value through Sep 2025 reached $2.9 billion, up 27.21%, while the annual FY2024 figure was $2.3 billion, 28.64% up from the prior year.
  • Long-Term Deferred Tax reached $2.9 billion in Q3 2025 per VRTX's latest filing, up from $2.7 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.9 billion in Q3 2025 and bottomed at $815.9 million in Q1 2021.
  • Average Long-Term Deferred Tax over 5 years is $1.7 billion, with a median of $1.5 billion recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: dropped 28.91% in 2021, then surged 48.71% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $934.5 million in 2021, then skyrocketed by 33.43% to $1.2 billion in 2022, then surged by 45.33% to $1.8 billion in 2023, then increased by 28.64% to $2.3 billion in 2024, then increased by 26.0% to $2.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $2.9 billion in Q3 2025, $2.7 billion in Q2 2025, and $2.5 billion in Q1 2025.